{ "FullStudy":{ "Rank":217621, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01519011", "OrgStudyIdInfo":{ "OrgStudyId":"AZA-MDS-004" }, "SecondaryIdInfoList":{ "SecondaryIdInfo":[ { "SecondaryId":"T-AZA-006", "SecondaryIdType":"Other Identifier", "SecondaryIdDomain":"Celgene" } ] }, "Organization":{ "OrgFullName":"Celgene", "OrgClass":"INDUSTRY" }, "BriefTitle":"Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine", "OfficialTitle":"A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA" }, "StatusModule":{ "StatusVerifiedDate":"November 2019", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"February 7, 2012", "StartDateType":"Actual" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"December 31, 2012", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"May 12, 2015", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 24, 2012", "StudyFirstSubmitQCDate":"January 24, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 26, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"November 7, 2019", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"November 12, 2019", "LastUpdatePostDateType":"Actual" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Celgene", "LeadSponsorClass":"INDUSTRY" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"The primary purpose of this study is to evaluate the pharmacokinetics of oral azacitidine when administered once daily as two 150-mg tablets, including the effect of food, and to evaluate the bioavailability of oral azacitidine 300-mg when administered as two 150-mg tablets relative to three 100-mg tablets." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Myelodysplastic Syndromes", "Leukemia, Myelomonocytic, Chronic", "Leukemia, Myeloid, Acute" ] }, "KeywordList":{ "Keyword":[ "Myelodysplastic Syndromes", "MDS", "Chronic Myelomonocytic Leukemia", "CMML", "Acute Myeloid Leukemia", "AML", "Vidaza", "oral azacitidine", "aza", "oral aza", "pharmacokinetics", "hematology", "myeloid disease", "PK" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 1" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Crossover Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"34", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"1: A, B, C", "ArmGroupType":"Experimental", "ArmGroupDescription":"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.\n\nDose C: Single oral administration with two 150-mg tablets under fed condition.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } },{ "ArmGroupLabel":"2: B, C, A", "ArmGroupType":"Experimental", "ArmGroupDescription":"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.\n\nDose C: Single oral administration with two 150-mg tablets under fed condition.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } },{ "ArmGroupLabel":"3: C, A, B", "ArmGroupType":"Experimental", "ArmGroupDescription":"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.\n\nDose C: Single oral administration with two 150-mg tablets under fed condition.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } },{ "ArmGroupLabel":"4: B, A, C", "ArmGroupType":"Experimental", "ArmGroupDescription":"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.\n\nDose C: Single oral administration with two 150-mg tablets under fed condition.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } },{ "ArmGroupLabel":"5: A, C, B", "ArmGroupType":"Experimental", "ArmGroupDescription":"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.\n\nDose C: Single oral administration with two 150-mg tablets under fed condition.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } },{ "ArmGroupLabel":"6: C, B, A", "ArmGroupType":"Experimental", "ArmGroupDescription":"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.\n\nDose C: Single oral administration with two 150-mg tablets under fed condition.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } },{ "ArmGroupLabel":"Extension", "ArmGroupType":"Experimental", "ArmGroupDescription":"300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: oral azacitidine" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"oral azacitidine", "InterventionDescription":"oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "1: A, B, C", "2: B, C, A", "3: C, A, B", "4: B, A, C", "5: A, C, B", "6: C, B, A" ] } },{ "InterventionType":"Drug", "InterventionName":"oral azacitidine", "InterventionDescription":"300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Extension" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"PK-(AUC)", "PrimaryOutcomeDescription":"PK-Area under the plasma concentration time curve (AUC)", "PrimaryOutcomeTimeFrame":"Up to 10 days" },{ "PrimaryOutcomeMeasure":"PK-(T½)", "PrimaryOutcomeDescription":"PK-Terminal half-life (T½)", "PrimaryOutcomeTimeFrame":"Up to 10 days" },{ "PrimaryOutcomeMeasure":"PK-(Cmax)", "PrimaryOutcomeDescription":"Observed maximum concentration in plasma (Cmax)", "PrimaryOutcomeTimeFrame":"Up to 10 days" },{ "PrimaryOutcomeMeasure":"PK-(Tmax)", "PrimaryOutcomeDescription":"PK-Time to maximum plasma concentration (Tmax)", "PrimaryOutcomeTimeFrame":"Up to 10 days" },{ "PrimaryOutcomeMeasure":"To evaluate the effect of gastric acid pH modulation, through a proton pump inhibitor, on the PK of oral azacitidine", "PrimaryOutcomeDescription":"To evaluate the effect of gastric acid pH modulation, through a proton pump inhibitor, on the PK of oral azacitidine.", "PrimaryOutcomeTimeFrame":"Up to 10 days" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Adverse Events", "SecondaryOutcomeDescription":"Number of participants with adverse events", "SecondaryOutcomeTimeFrame":"Up to 2 years" },{ "SecondaryOutcomeMeasure":"Hematological response/improvement", "SecondaryOutcomeDescription":"Proportion of subjects achieving hematological response/improvement", "SecondaryOutcomeTimeFrame":"Up to 2 years" },{ "SecondaryOutcomeMeasure":"Transfusion independence", "SecondaryOutcomeDescription":"Proportion of subjects achieving RBC transfusion independence", "SecondaryOutcomeTimeFrame":"Up to 2 years" },{ "SecondaryOutcomeMeasure":"Platelet transfusion independence", "SecondaryOutcomeDescription":"Proportion of subjects achieving platelet transfusion independence", "SecondaryOutcomeTimeFrame":"Up to 2 years" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nAge 18 years or older at the time of signing the informed consent document\nDiagnosis of Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\nAt least 3 month life expectancy\n\nAdequate organ function, defined as:\n\nSerum bilirubin ≤ 1.5 times the upper limit of normal (ULN);\nSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the ULN;\nSerum creatinine ≤ 1.5 times the ULN;\nSerum bicarbonate ≥ 20 mEq/L\n\nFemales of childbearing potential (FCBP) must:\n\nAgree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study, and for 3 months following the last dose of oral azacitidine; and\nHave a negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) at screening; and\nHave a negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) within 72 hours prior to Day 1 of the pharmacokinetic (PK) phase (note that the screening pregnancy test can be used as the test prior to Day 1 of the PK phase if it is performed within the 72 hour timeframe).\nMales with partners who are FCBP must agree that they and their partners will use at least two effective contraceptive methods throughout the study and will avoid fathering a child for 3 months following the date of last oral azacitidine dosing\nUnderstand and voluntarily sign an informed consent document prior to the start of any study related assessments/procedures\nAble to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\nSuspected or proven acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype\nPrevious treatment with azacitidine or other demethylating agents within 21 days prior to starting study therapy or ongoing adverse events from previous treatment, regardless of the time period\nAnticancer therapy (standard or investigational) within 21 days prior to starting study therapy or ongoing adverse events from previous treatment, regardless of the time period\nUse of any proton pump inhibitor or any other agent that may affect gastric acid level within 28 days prior to study therapy (only applicable to Part II of the PK phase)\nConcurrent use of erythropoiesis-stimulating agents (ESAs) and other red blood cell hematopoietic growth factors, except that the subject is on a stable dose for at least 4 weeks (28 days) prior to starting study therapy\nConcurrent use of iron-chelating agents, except that the subject is on a stable dose for at least 8 weeks (56 days) prior to starting study therapy\nConcurrent corticosteroid use, except for medical conditions other than Myelodysplastic Syndrome and provided the subject is on a stable or decreasing dose for ≥ 1 week prior to start study therapy\nPregnant or lactating females\nAny known or suspected hypersensitivity to azacitidine or mannitol or any other ingredient used in the manufacture of oral azacitidine (see the azacitidine IB)\nUncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment)\nActive viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C\nPresence of gastrointestinal disease, malignant hepatic tumors, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs\nCurrent congestive heart failure (New York Heart Association Class III-IV Appendix G), unstable angina or angina requiring surgical or medical intervention within 6 months prior to starting study therapy, myocardial infarct within 6 months prior to starting study therapy, or uncontrolled cardiac arrhythmia (defined as arrhythmia that is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia). Subjects with controlled atrial fibrillation that is asymptomatic are eligible\nAny significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study\nAny condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study\nAny condition that confounds the ability to interpret data from the study", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"18 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Barry Skikne, M.D.", "OverallOfficialAffiliation":"Celgene", "OverallOfficialRole":"Study Director" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Moores UCSD Cancer Center MC-0987", "LocationCity":"La Jolla", "LocationState":"California", "LocationZip":"92093", "LocationCountry":"United States" },{ "LocationFacility":"Rocky Mountain Cancer Center", "LocationCity":"Denver", "LocationState":"Colorado", "LocationZip":"80218-1210", "LocationCountry":"United States" },{ "LocationFacility":"Comprehensive Cancer Centers of Nevada", "LocationCity":"Las Vegas", "LocationState":"Nevada", "LocationZip":"89169", "LocationCountry":"United States" },{ "LocationFacility":"University of Cincinnati Physician's Inc.", "LocationCity":"Cincinnati", "LocationState":"Ohio", "LocationZip":"45267-0562", "LocationCountry":"United States" },{ "LocationFacility":"Sarah Cannon Cancer Center", "LocationCity":"Nashville", "LocationState":"Tennessee", "LocationZip":"37203", "LocationCountry":"United States" },{ "LocationFacility":"Texas Oncology", "LocationCity":"Dallas", "LocationState":"Texas", "LocationZip":"75230", "LocationCountry":"United States" },{ "LocationFacility":"Virginia Oncology Associates", "LocationCity":"Norfolk", "LocationState":"Virginia", "LocationZip":"23502", "LocationCountry":"United States" },{ "LocationFacility":"Northwest Cancer Specialists, P.C.", "LocationCity":"Vancouver", "LocationState":"Washington", "LocationZip":"98684", "LocationCountry":"United States" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"24374798", "ReferenceType":"background", "ReferenceCitation":"Laille E, Savona MR, Scott BL, Boyd TE, Dong Q, Skikne B. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. J Clin Pharmacol. 2014 Jun;54(6):630-9. doi: 10.1002/jcph.251. Epub 2014 Jan 18." },{ "ReferencePMID":"30016552", "ReferenceType":"background", "ReferenceCitation":"Savona MR, Kolibaba K, Conkling P, Kingsley EC, Becerra C, Morris JC, Rifkin RM, Laille E, Kellerman A, Ukrainskyj SM, Dong Q, Skikne BS. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018 Oct;93(10):1199-1206. doi: 10.1002/ajh.25216. Epub 2018 Sep 3." } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000001374", "InterventionMeshTerm":"Azacitidine" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000964", "InterventionAncestorTerm":"Antimetabolites, Antineoplastic" },{ "InterventionAncestorId":"D000000963", "InterventionAncestorTerm":"Antimetabolites" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" },{ "InterventionAncestorId":"D000000970", "InterventionAncestorTerm":"Antineoplastic Agents" },{ "InterventionAncestorId":"D000004791", "InterventionAncestorTerm":"Enzyme Inhibitors" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M3254", "InterventionBrowseLeafName":"Azacitidine", "InterventionBrowseLeafAsFound":"Azacitidine", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2862", "InterventionBrowseLeafName":"Antimetabolites", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"ANeo", "InterventionBrowseBranchName":"Antineoplastic Agents" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000007938", "ConditionMeshTerm":"Leukemia" },{ "ConditionMeshId":"D000011289", "ConditionMeshTerm":"Preleukemia" },{ "ConditionMeshId":"D000015477", "ConditionMeshTerm":"Leukemia, Myelomonocytic, Chronic" },{ "ConditionMeshId":"D000007951", "ConditionMeshTerm":"Leukemia, Myeloid" },{ "ConditionMeshId":"D000015470", "ConditionMeshTerm":"Leukemia, Myeloid, Acute" },{ "ConditionMeshId":"D000009190", "ConditionMeshTerm":"Myelodysplastic Syndromes" },{ "ConditionMeshId":"D000013577", "ConditionMeshTerm":"Syndrome" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000004194", "ConditionAncestorTerm":"Disease" },{ "ConditionAncestorId":"D000010335", "ConditionAncestorTerm":"Pathologic Processes" },{ "ConditionAncestorId":"D000009370", "ConditionAncestorTerm":"Neoplasms by Histologic Type" },{ "ConditionAncestorId":"D000009369", "ConditionAncestorTerm":"Neoplasms" },{ "ConditionAncestorId":"D000001855", "ConditionAncestorTerm":"Bone Marrow Diseases" },{ "ConditionAncestorId":"D000006402", "ConditionAncestorTerm":"Hematologic Diseases" },{ "ConditionAncestorId":"D000011230", "ConditionAncestorTerm":"Precancerous Conditions" },{ "ConditionAncestorId":"D000054437", "ConditionAncestorTerm":"Myelodysplastic-Myeloproliferative Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M14938", "ConditionBrowseLeafName":"Syndrome", "ConditionBrowseLeafAsFound":"Syndrome", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M9528", "ConditionBrowseLeafName":"Leukemia", "ConditionBrowseLeafAsFound":"Leukemia", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M9538", "ConditionBrowseLeafName":"Leukemia, Myeloid", "ConditionBrowseLeafAsFound":"Leukemia, Myeloid", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M16710", "ConditionBrowseLeafName":"Leukemia, Myeloid, Acute", "ConditionBrowseLeafAsFound":"Leukemia, Myeloid, Acute", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M12747", "ConditionBrowseLeafName":"Preleukemia", "ConditionBrowseLeafAsFound":"Myelodysplastic Syndrome", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M10728", "ConditionBrowseLeafName":"Myelodysplastic Syndromes", "ConditionBrowseLeafAsFound":"Myelodysplastic Syndrome", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M16715", "ConditionBrowseLeafName":"Leukemia, Myelomonocytic, Chronic", "ConditionBrowseLeafAsFound":"Leukemia, Myelomonocytic, Chronic", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M26293", "ConditionBrowseLeafName":"Leukemia, Myelomonocytic, Juvenile", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10898", "ConditionBrowseLeafName":"Neoplasms by Histologic Type", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M3716", "ConditionBrowseLeafName":"Bone Marrow Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8073", "ConditionBrowseLeafName":"Hematologic Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M12694", "ConditionBrowseLeafName":"Precancerous Conditions", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10732", "ConditionBrowseLeafName":"Myeloproliferative Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M26294", "ConditionBrowseLeafName":"Myelodysplastic-Myeloproliferative Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"T4021", "ConditionBrowseLeafName":"Myeloid Leukemia", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"T181", "ConditionBrowseLeafName":"Acute Myeloid Leukemia", "ConditionBrowseLeafAsFound":"Leukemia, Myeloid, Acute", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"T187", "ConditionBrowseLeafName":"Acute Non Lymphoblastic Leukemia", "ConditionBrowseLeafAsFound":"Leukemia, Myeloid, Acute", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"T4018", "ConditionBrowseLeafName":"Myelodysplastic Syndromes", "ConditionBrowseLeafAsFound":"Myelodysplastic Syndrome", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"T1317", "ConditionBrowseLeafName":"Chronic Myelomonocytic Leukemia", "ConditionBrowseLeafAsFound":"Leukemia, Myelomonocytic, Chronic", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"T3186", "ConditionBrowseLeafName":"Juvenile Myelomonocytic Leukemia", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"T4019", "ConditionBrowseLeafName":"Myelodysplastic/myeloproliferative Disease", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC04", "ConditionBrowseBranchName":"Cancers and Other Neoplasms" },{ "ConditionBrowseBranchAbbrev":"BC15", "ConditionBrowseBranchName":"Blood and Lymph Conditions" },{ "ConditionBrowseBranchAbbrev":"Rare", "ConditionBrowseBranchName":"Rare Diseases" } ] } } } } } }